Biology & Ecology
Biology
Gram Statusgram-positive
Oxygen Toleranceobligate anaerobe
Morphologybacillus (rod)
Ecology
Primary Nichesgut
Reservoirhuman
Clinical Profile
Pathobiont
yes
no
context dependent
unknown
Clinical Rolescommensal
Typical Specimenblood; stool
Bloom Triggers
immunosuppression
Risk Contextsmelanoma patients receiving immune checkpoint inhibitor therapy (ICB)
AMR Highlights
none documented
Virulence Factors
none documented
Clinical Associations:
E2
E3 — Strong human clinical evidence
E2 — Moderate human evidence
E1 — Limited / preliminary
Enterocloster clostridioformis was among organisms enriched in responders (objective response or stable disease >12 months) to FMT plus pembrolizumab in a Phase 2 trial of 15 PD-1-refractory advanced melanoma patients, as identified by transkingdom multi-omic network analysis (Fig. 4E).
PMID:
33542131
Last reviewed: 2026-04-02
Evidence Timeline
Related Taxa
Shared Niche = same body site
Shared Risk = same vulnerable population
ⓘ